Literature DB >> 21907323

Serotonergic and noradrenergic pathways are required for the anxiolytic-like and antidepressant-like behavioral effects of repeated vagal nerve stimulation in rats.

Havan Furmaga1, Aparna Shah, Alan Frazer.   

Abstract

BACKGROUND: Vagal nerve stimulation (VNS) is used for treatment-refractory depression, but there are few preclinical studies of its effects when administered repeatedly over time using clinically relevant stimulation parameters in nonanesthetized animals.
METHODS: The novelty-suppressed feeding test (NSFT) and forced swim test (FST) were used to evaluate the anxiolytic- and antidepressant-like potential of VNS in rats, respectively. The behavioral effects of VNS were compared with those of desipramine (DMI; 10 mg/kg/day) and sertraline (7.5 mg/kg/day) administered via osmotic minipump. Such experiments were carried out in intact rats as well as those that had selective destruction of either serotonin or noradrenergic neurons in brain caused by the neurotoxins, 5,7-dihyroxytryptamine (5,7-DHT), or 6-hydroxydopamine (6-OHDA).
RESULTS: Repeated administration of VNS, DMI, and sertraline decreased latency to feed in the NSFT. In the FST, repeated VNS, DMI, and sertraline caused decreased immobility; the VNS-induced decrease in immobility resulted from increases in both swimming and climbing behaviors. Effects of VNS and sertraline, but not DMI, in both the NSFT and the FST were abolished in rats treated with 5,7-DHT. Effects of DMI in both behavioral tests, but not those of sertraline, were abolished in 6-OHDA treated rats. VNS effects on immobility and climbing in the FST were not blocked in the 6-OHDA-treated rats. There was no significant difference in locomotor activity caused by any of the treatments or by the lesions.
CONCLUSIONS: Serotonergic nerves are required for repeated VNS-induced anxiolytic- and antidepressant-like effects. Noradrenergic nerves can also be activated by VNS to cause its anxiolytic-like effect.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907323     DOI: 10.1016/j.biopsych.2011.07.020

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  37 in total

1.  Comparison of ΔFosB immunoreactivity induced by vagal nerve stimulation with that caused by pharmacologically diverse antidepressants.

Authors:  Havan Furmaga; Mohona Sadhu; Alan Frazer
Journal:  J Pharmacol Exp Ther       Date:  2012-01-27       Impact factor: 4.030

2.  Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats.

Authors:  Saloua Benmansour; Opeyemi S Adeniji; Anthony A Privratsky; Alan Frazer
Journal:  Neuroendocrinology       Date:  2015-07-01       Impact factor: 4.914

3.  Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.

Authors:  Ariana Q Farrand; Kristi L Helke; Rebecca A Gregory; Monika Gooz; Vanessa K Hinson; Heather A Boger
Journal:  Brain Stimul       Date:  2017-08-24       Impact factor: 8.955

4.  Parametric characterization of neural activity in the locus coeruleus in response to vagus nerve stimulation.

Authors:  Daniel R Hulsey; Jonathan R Riley; Kristofer W Loerwald; Robert L Rennaker; Michael P Kilgard; Seth A Hays
Journal:  Exp Neurol       Date:  2016-12-14       Impact factor: 5.330

5.  Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT₁a receptor antagonist.

Authors:  Anshul A Pandya; Jerrel L Yakel
Journal:  Neuropharmacology       Date:  2013-01-12       Impact factor: 5.250

6.  Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity.

Authors:  Megan K Roth; Brian Bingham; Aparna Shah; Ankur Joshi; Alan Frazer; Randy Strong; David A Morilak
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

7.  Rapid remission of conditioned fear expression with extinction training paired with vagus nerve stimulation.

Authors:  David F Peña; Navzer D Engineer; Christa K McIntyre
Journal:  Biol Psychiatry       Date:  2012-12-13       Impact factor: 13.382

8.  [Treatment of epilepsy: peripheral and central stimulation techniques].

Authors:  A Schulze-Bonhage; V Coenen
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

9.  Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.

Authors:  Chen-Cheng Lin; Che-Se Tung; Yia-Ping Liu
Journal:  Psychopharmacology (Berl)       Date:  2016-01-07       Impact factor: 4.530

10.  Modulating the modulators: interaction of brain norepinephrine and cannabinoids in stress.

Authors:  David A Morilak
Journal:  Exp Neurol       Date:  2012-08-19       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.